Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Preimplantation Genetic Testing Market by Product (Reagents Consumables, Instruments), by Procedure (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), by Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism) and by Application (Aneuploidy, Single Gene Disorder, Structural Chromosomal Abnormalities, X-Linked Disorders, Human Leukocyte Typing, Gender Identification.): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03441

Pages: NA

Charts: NA

Tables: NA

Preimplantation genetic testing is performed prior to implantation that assists in the diagnosis of genetic defects present within the embryos. Preimplantation genetic testing helps analyze the genetic profile of embryos, which helps avoid selective pregnancy termination. In this process, a cell from an IVF embryo that is to be tested is removed before transferring the embryo to the uterus. The removed cell is tested for a specific genetic condition (for instance, cystic fibrosis).

The key factors that drive the market growth include technological advancements in the field of genetic analysis and high risk of chromosomal abnormalities with increased maternal age. In addition, factors such as infertility issues among men and women also fuel the market growth. However, high costs associated with preimplantation genetic testing and unfavorable government regulations restrain the market growth. Increasing awareness about preimplantation genetic testing and growing medical tourism will offer lucrative opportunities for the market growth.

This report segments the global preimplantation genetic testing market based on product, procedure, technology, application, end user, and region. Based on products, the market is segmented into reagents & consumables and instruments. Based on procedure, the market is segmented into preimplantation genetic screening and preimplantation genetic diagnosis. Based on technology, the market is segmented into next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization, and single-nucleotide polymorphism. Based on application, the market can be segmented into aneuploidy, single gene disorder, structural chromosomal abnormalities, X-linked disorders, human leukocyte typing, and gender identification. Based on region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players of the market included in the report are Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Coopersurgical, Inc., Abbott Laboratories, Natera, Inc., Oxford Gene Technology, Yikon Genomics, and SciGene Corporation.

Key Benefits

  • The study provides an in-depth analysis of the global preimplantation genetic testing market, with current trends and future estimations to elucidate imminent investment pockets.
  • It presents a quantitative analysis to enable stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by product elucidates various forms of available preimplantation genetic testing methods.
  • Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.
  • By region, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Market Segments

  • By Product
    • Reagents & Consumables
    • Instruments
  • By Procedure
    • Preimplantation Genetic Screening
    • Preimplantation Genetic Diagnosis
  • By Technology
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
    • Fluorescence in Situ Hybridization
    • Comparative Genomic Hybridization
    • Single-Nucleotide Polymorphism
  • By Application
    • Aneuploidy
    • Single Gene Disorder
    • Structural Chromosomal Abnormalities
      • Translocations
      • Deletions
      • Duplications
      • Inversions
    • X-Linked Disorders
    • Human Leukocyte Typing
    • Gender Identification.
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Argentina
      • Rest of LAMEA


Key Market Players

  • Illumina, Inc.
  • SciGene Corporation
  • Yikon Genomics
  • Agilent Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Natera, Inc.
  • PerkinElmer Inc.
  • Coopersurgical, Inc.
  • Abbott Laboratories
  • Oxford Gene Technology
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Reagents And Consumables

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Instruments

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Procedure

    • 5.2. Preimplantation Genetic Screening

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Preimplantation Genetic Diagnosis

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Technology

    • 6.2. Next-Generation Sequencing

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Polymerase Chain Reaction

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Fluorescence In Situ Hybridization

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Comparative Genomic Hybridization

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Single-Nucleotide Polymorphism

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

  • CHAPTER 7: PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Application

    • 7.2. Aneuploidy

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Single Gene Disorder

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Structural Chromosomal Abnormalities

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

      • 7.4.4. Translocations

        • 7.4.4.1. Market Size and Forecast
      • 7.4.4. Deletions

        • 7.4.4.1. Market Size and Forecast
      • 7.4.4. Duplications

        • 7.4.4.1. Market Size and Forecast
      • 7.4.4. Inversions

        • 7.4.4.1. Market Size and Forecast
    • 7.5. X-Linked Disorders

      • 7.5.1. Key Market Trends, Growth Factors and Opportunities

      • 7.5.2. Market Size and Forecast, By Region

      • 7.5.3. Market Share Analysis, By Country

    • 7.6. Human Leukocyte Typing

      • 7.6.1. Key Market Trends, Growth Factors and Opportunities

      • 7.6.2. Market Size and Forecast, By Region

      • 7.6.3. Market Share Analysis, By Country

    • 7.7. Gender Identification.

      • 7.7.1. Key Market Trends, Growth Factors and Opportunities

      • 7.7.2. Market Size and Forecast, By Region

      • 7.7.3. Market Share Analysis, By Country

  • CHAPTER 8: PREIMPLANTATION GENETIC TESTING MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product

      • 8.2.3. Market Size and Forecast, By Procedure

      • 8.2.4. Market Size and Forecast, By Technology

      • 8.2.5. Market Size and Forecast, By Application

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Preimplantation Genetic Testing Market

        • 8.2.7.1. Market Size and Forecast, By Product
        • 8.2.7.2. Market Size and Forecast, By Procedure
        • 8.2.7.3. Market Size and Forecast, By Technology
        • 8.2.7.4. Market Size and Forecast, By Application
      • 8.2.8. Canada Preimplantation Genetic Testing Market

        • 8.2.8.1. Market Size and Forecast, By Product
        • 8.2.8.2. Market Size and Forecast, By Procedure
        • 8.2.8.3. Market Size and Forecast, By Technology
        • 8.2.8.4. Market Size and Forecast, By Application
      • 8.2.9. Mexico Preimplantation Genetic Testing Market

        • 8.2.9.1. Market Size and Forecast, By Product
        • 8.2.9.2. Market Size and Forecast, By Procedure
        • 8.2.9.3. Market Size and Forecast, By Technology
        • 8.2.9.4. Market Size and Forecast, By Application
    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product

      • 8.3.3. Market Size and Forecast, By Procedure

      • 8.3.4. Market Size and Forecast, By Technology

      • 8.3.5. Market Size and Forecast, By Application

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Preimplantation Genetic Testing Market

        • 8.3.7.1. Market Size and Forecast, By Product
        • 8.3.7.2. Market Size and Forecast, By Procedure
        • 8.3.7.3. Market Size and Forecast, By Technology
        • 8.3.7.4. Market Size and Forecast, By Application
      • 8.3.8. Germany Preimplantation Genetic Testing Market

        • 8.3.8.1. Market Size and Forecast, By Product
        • 8.3.8.2. Market Size and Forecast, By Procedure
        • 8.3.8.3. Market Size and Forecast, By Technology
        • 8.3.8.4. Market Size and Forecast, By Application
      • 8.3.9. Italy Preimplantation Genetic Testing Market

        • 8.3.9.1. Market Size and Forecast, By Product
        • 8.3.9.2. Market Size and Forecast, By Procedure
        • 8.3.9.3. Market Size and Forecast, By Technology
        • 8.3.9.4. Market Size and Forecast, By Application
      • 8.3.10. Spain Preimplantation Genetic Testing Market

        • 8.3.10.1. Market Size and Forecast, By Product
        • 8.3.10.2. Market Size and Forecast, By Procedure
        • 8.3.10.3. Market Size and Forecast, By Technology
        • 8.3.10.4. Market Size and Forecast, By Application
      • 8.3.11. UK Preimplantation Genetic Testing Market

        • 8.3.11.1. Market Size and Forecast, By Product
        • 8.3.11.2. Market Size and Forecast, By Procedure
        • 8.3.11.3. Market Size and Forecast, By Technology
        • 8.3.11.4. Market Size and Forecast, By Application
      • 8.3.12. Russia Preimplantation Genetic Testing Market

        • 8.3.12.1. Market Size and Forecast, By Product
        • 8.3.12.2. Market Size and Forecast, By Procedure
        • 8.3.12.3. Market Size and Forecast, By Technology
        • 8.3.12.4. Market Size and Forecast, By Application
      • 8.3.13. Rest Of Europe Preimplantation Genetic Testing Market

        • 8.3.13.1. Market Size and Forecast, By Product
        • 8.3.13.2. Market Size and Forecast, By Procedure
        • 8.3.13.3. Market Size and Forecast, By Technology
        • 8.3.13.4. Market Size and Forecast, By Application
    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product

      • 8.4.3. Market Size and Forecast, By Procedure

      • 8.4.4. Market Size and Forecast, By Technology

      • 8.4.5. Market Size and Forecast, By Application

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Preimplantation Genetic Testing Market

        • 8.4.7.1. Market Size and Forecast, By Product
        • 8.4.7.2. Market Size and Forecast, By Procedure
        • 8.4.7.3. Market Size and Forecast, By Technology
        • 8.4.7.4. Market Size and Forecast, By Application
      • 8.4.8. Japan Preimplantation Genetic Testing Market

        • 8.4.8.1. Market Size and Forecast, By Product
        • 8.4.8.2. Market Size and Forecast, By Procedure
        • 8.4.8.3. Market Size and Forecast, By Technology
        • 8.4.8.4. Market Size and Forecast, By Application
      • 8.4.9. India Preimplantation Genetic Testing Market

        • 8.4.9.1. Market Size and Forecast, By Product
        • 8.4.9.2. Market Size and Forecast, By Procedure
        • 8.4.9.3. Market Size and Forecast, By Technology
        • 8.4.9.4. Market Size and Forecast, By Application
      • 8.4.10. South Korea Preimplantation Genetic Testing Market

        • 8.4.10.1. Market Size and Forecast, By Product
        • 8.4.10.2. Market Size and Forecast, By Procedure
        • 8.4.10.3. Market Size and Forecast, By Technology
        • 8.4.10.4. Market Size and Forecast, By Application
      • 8.4.11. Australia Preimplantation Genetic Testing Market

        • 8.4.11.1. Market Size and Forecast, By Product
        • 8.4.11.2. Market Size and Forecast, By Procedure
        • 8.4.11.3. Market Size and Forecast, By Technology
        • 8.4.11.4. Market Size and Forecast, By Application
      • 8.4.12. Thailand Preimplantation Genetic Testing Market

        • 8.4.12.1. Market Size and Forecast, By Product
        • 8.4.12.2. Market Size and Forecast, By Procedure
        • 8.4.12.3. Market Size and Forecast, By Technology
        • 8.4.12.4. Market Size and Forecast, By Application
      • 8.4.13. Malaysia Preimplantation Genetic Testing Market

        • 8.4.13.1. Market Size and Forecast, By Product
        • 8.4.13.2. Market Size and Forecast, By Procedure
        • 8.4.13.3. Market Size and Forecast, By Technology
        • 8.4.13.4. Market Size and Forecast, By Application
      • 8.4.14. Indonesia Preimplantation Genetic Testing Market

        • 8.4.14.1. Market Size and Forecast, By Product
        • 8.4.14.2. Market Size and Forecast, By Procedure
        • 8.4.14.3. Market Size and Forecast, By Technology
        • 8.4.14.4. Market Size and Forecast, By Application
      • 8.4.15. Rest of Asia Pacific Preimplantation Genetic Testing Market

        • 8.4.15.1. Market Size and Forecast, By Product
        • 8.4.15.2. Market Size and Forecast, By Procedure
        • 8.4.15.3. Market Size and Forecast, By Technology
        • 8.4.15.4. Market Size and Forecast, By Application
    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product

      • 8.5.3. Market Size and Forecast, By Procedure

      • 8.5.4. Market Size and Forecast, By Technology

      • 8.5.5. Market Size and Forecast, By Application

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Preimplantation Genetic Testing Market

        • 8.5.7.1. Market Size and Forecast, By Product
        • 8.5.7.2. Market Size and Forecast, By Procedure
        • 8.5.7.3. Market Size and Forecast, By Technology
        • 8.5.7.4. Market Size and Forecast, By Application
      • 8.5.8. South Africa Preimplantation Genetic Testing Market

        • 8.5.8.1. Market Size and Forecast, By Product
        • 8.5.8.2. Market Size and Forecast, By Procedure
        • 8.5.8.3. Market Size and Forecast, By Technology
        • 8.5.8.4. Market Size and Forecast, By Application
      • 8.5.9. Saudi Arabia Preimplantation Genetic Testing Market

        • 8.5.9.1. Market Size and Forecast, By Product
        • 8.5.9.2. Market Size and Forecast, By Procedure
        • 8.5.9.3. Market Size and Forecast, By Technology
        • 8.5.9.4. Market Size and Forecast, By Application
      • 8.5.10. UAE Preimplantation Genetic Testing Market

        • 8.5.10.1. Market Size and Forecast, By Product
        • 8.5.10.2. Market Size and Forecast, By Procedure
        • 8.5.10.3. Market Size and Forecast, By Technology
        • 8.5.10.4. Market Size and Forecast, By Application
      • 8.5.11. Argentina Preimplantation Genetic Testing Market

        • 8.5.11.1. Market Size and Forecast, By Product
        • 8.5.11.2. Market Size and Forecast, By Procedure
        • 8.5.11.3. Market Size and Forecast, By Technology
        • 8.5.11.4. Market Size and Forecast, By Application
      • 8.5.12. Rest of LAMEA Preimplantation Genetic Testing Market

        • 8.5.12.1. Market Size and Forecast, By Product
        • 8.5.12.2. Market Size and Forecast, By Procedure
        • 8.5.12.3. Market Size and Forecast, By Technology
        • 8.5.12.4. Market Size and Forecast, By Application
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning, 2024

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Illumina, Inc.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Thermo Fisher Scientific Inc.

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. Agilent Technologies Inc.

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. PerkinElmer Inc.

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Coopersurgical, Inc.

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Abbott Laboratories

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Natera, Inc.

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Oxford Gene Technology

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. Yikon Genomics

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. SciGene Corporation

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR INSTRUMENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR PREIMPLANTATION GENETIC SCREENING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR HUMAN LEUKOCYTE TYPING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION., BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. NORTH AMERICA PREIMPLANTATION GENETIC TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. NORTH AMERICA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 23. NORTH AMERICA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 24. NORTH AMERICA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 25. NORTH AMERICA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 26. U.S. PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 27. U.S. PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 28. U.S. PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 29. U.S. PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 30. CANADA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 31. CANADA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 32. CANADA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 33. CANADA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 34. MEXICO PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 35. MEXICO PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 36. MEXICO PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 37. MEXICO PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 38. EUROPE PREIMPLANTATION GENETIC TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. EUROPE PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 40. EUROPE PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 41. EUROPE PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 42. EUROPE PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 43. FRANCE PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 44. FRANCE PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 45. FRANCE PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 46. FRANCE PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 47. GERMANY PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 48. GERMANY PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 49. GERMANY PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 50. GERMANY PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 51. ITALY PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 52. ITALY PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 53. ITALY PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 54. ITALY PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 55. SPAIN PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 56. SPAIN PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 57. SPAIN PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 58. SPAIN PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 59. UK PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 60. UK PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 61. UK PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 62. UK PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 63. RUSSIA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 64. RUSSIA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 65. RUSSIA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 66. RUSSIA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 67. REST OF EUROPE PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 68. REST OF EUROPE PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 69. REST OF EUROPE PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 70. REST OF EUROPE PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 71. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 72. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 73. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 74. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 75. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 76. CHINA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 77. CHINA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 78. CHINA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 79. CHINA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 80. JAPAN PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 81. JAPAN PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 82. JAPAN PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 83. JAPAN PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 84. INDIA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 85. INDIA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 86. INDIA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 87. INDIA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 88. SOUTH KOREA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 89. SOUTH KOREA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 90. SOUTH KOREA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH KOREA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 92. AUSTRALIA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 93. AUSTRALIA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 94. AUSTRALIA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 95. AUSTRALIA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 96. THAILAND PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 97. THAILAND PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 98. THAILAND PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 99. THAILAND PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 100. MALAYSIA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 101. MALAYSIA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 102. MALAYSIA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 103. MALAYSIA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 104. INDONESIA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 105. INDONESIA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 106. INDONESIA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 107. INDONESIA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 108. REST OF ASIA PACIFIC PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 111. REST OF ASIA PACIFIC PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 112. LAMEA PREIMPLANTATION GENETIC TESTING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 113. LAMEA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 114. LAMEA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 115. LAMEA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 116. LAMEA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 117. BRAZIL PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 118. BRAZIL PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 119. BRAZIL PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 120. BRAZIL PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 121. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 122. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 123. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 124. SOUTH AFRICA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 125. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 126. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 127. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 128. SAUDI ARABIA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 129. UAE PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 130. UAE PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 131. UAE PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 132. UAE PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 133. ARGENTINA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 134. ARGENTINA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 135. ARGENTINA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 136. ARGENTINA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 137. REST OF LAMEA PREIMPLANTATION GENETIC TESTING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 138. REST OF LAMEA PREIMPLANTATION GENETIC TESTING, BY PROCEDURE, 2025-2033 ($MILLION)
  • TABLE 139. REST OF LAMEA PREIMPLANTATION GENETIC TESTING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 140. REST OF LAMEA PREIMPLANTATION GENETIC TESTING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 141. ILLUMINA, INC.: KEY EXECUTIVES
  • TABLE 142. ILLUMINA, INC.: COMPANY SNAPSHOT
  • TABLE 143. ILLUMINA, INC.: OPERATING SEGMENTS
  • TABLE 144. ILLUMINA, INC.: PRODUCT PORTFOLIO
  • TABLE 145. ILLUMINA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 147. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 148. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 149. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 150. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. AGILENT TECHNOLOGIES INC.: KEY EXECUTIVES
  • TABLE 152. AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 153. AGILENT TECHNOLOGIES INC.: OPERATING SEGMENTS
  • TABLE 154. AGILENT TECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 155. AGILENT TECHNOLOGIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. PERKINELMER INC.: KEY EXECUTIVES
  • TABLE 157. PERKINELMER INC.: COMPANY SNAPSHOT
  • TABLE 158. PERKINELMER INC.: OPERATING SEGMENTS
  • TABLE 159. PERKINELMER INC.: PRODUCT PORTFOLIO
  • TABLE 160. PERKINELMER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161. COOPERSURGICAL, INC.: KEY EXECUTIVES
  • TABLE 162. COOPERSURGICAL, INC.: COMPANY SNAPSHOT
  • TABLE 163. COOPERSURGICAL, INC.: OPERATING SEGMENTS
  • TABLE 164. COOPERSURGICAL, INC.: PRODUCT PORTFOLIO
  • TABLE 165. COOPERSURGICAL, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 166. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 167. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 168. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 169. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 170. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 171. NATERA, INC.: KEY EXECUTIVES
  • TABLE 172. NATERA, INC.: COMPANY SNAPSHOT
  • TABLE 173. NATERA, INC.: OPERATING SEGMENTS
  • TABLE 174. NATERA, INC.: PRODUCT PORTFOLIO
  • TABLE 175. NATERA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 176. OXFORD GENE TECHNOLOGY: KEY EXECUTIVES
  • TABLE 177. OXFORD GENE TECHNOLOGY: COMPANY SNAPSHOT
  • TABLE 178. OXFORD GENE TECHNOLOGY: OPERATING SEGMENTS
  • TABLE 179. OXFORD GENE TECHNOLOGY: PRODUCT PORTFOLIO
  • TABLE 180. OXFORD GENE TECHNOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 181. YIKON GENOMICS: KEY EXECUTIVES
  • TABLE 182. YIKON GENOMICS: COMPANY SNAPSHOT
  • TABLE 183. YIKON GENOMICS: OPERATING SEGMENTS
  • TABLE 184. YIKON GENOMICS: PRODUCT PORTFOLIO
  • TABLE 185. YIKON GENOMICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 186. SCIGENE CORPORATION: KEY EXECUTIVES
  • TABLE 187. SCIGENE CORPORATION: COMPANY SNAPSHOT
  • TABLE 188. SCIGENE CORPORATION: OPERATING SEGMENTS
  • TABLE 189. SCIGENE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 190. SCIGENE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET
  • FIGURE 3. SEGMENTATION PREIMPLANTATION GENETIC TESTING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PREIMPLANTATION GENETIC TESTING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPREIMPLANTATION GENETIC TESTING MARKET
  • FIGURE 11. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. PREIMPLANTATION GENETIC TESTING MARKET FOR REAGENTS AND CONSUMABLES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. PREIMPLANTATION GENETIC TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION, BY BY PROCEDURE
  • FIGURE 15. PREIMPLANTATION GENETIC TESTING MARKET FOR PREIMPLANTATION GENETIC SCREENING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. PREIMPLANTATION GENETIC TESTING MARKET FOR PREIMPLANTATION GENETIC DIAGNOSIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 18. PREIMPLANTATION GENETIC TESTING MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. PREIMPLANTATION GENETIC TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. PREIMPLANTATION GENETIC TESTING MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. PREIMPLANTATION GENETIC TESTING MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE-NUCLEOTIDE POLYMORPHISM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 24. PREIMPLANTATION GENETIC TESTING MARKET FOR ANEUPLOIDY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. PREIMPLANTATION GENETIC TESTING MARKET FOR SINGLE GENE DISORDER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. PREIMPLANTATION GENETIC TESTING MARKET FOR STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. PREIMPLANTATION GENETIC TESTING MARKET FOR X-LINKED DISORDERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. PREIMPLANTATION GENETIC TESTING MARKET FOR HUMAN LEUKOCYTE TYPING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 29. PREIMPLANTATION GENETIC TESTING MARKET FOR GENDER IDENTIFICATION., BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 30. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 31. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 32. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 33. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 34. COMPETITIVE DASHBOARD
  • FIGURE 35. COMPETITIVE HEATMAP: PREIMPLANTATION GENETIC TESTING MARKET
  • FIGURE 36. TOP PLAYER POSITIONING, 2024
  • FIGURE 37. ILLUMINA, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. ILLUMINA, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. ILLUMINA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. AGILENT TECHNOLOGIES INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. AGILENT TECHNOLOGIES INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. AGILENT TECHNOLOGIES INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. PERKINELMER INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. PERKINELMER INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. PERKINELMER INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. COOPERSURGICAL, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. COOPERSURGICAL, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. COOPERSURGICAL, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. NATERA, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. NATERA, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. NATERA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 58. OXFORD GENE TECHNOLOGY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 59. OXFORD GENE TECHNOLOGY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 60. OXFORD GENE TECHNOLOGY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 61. YIKON GENOMICS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 62. YIKON GENOMICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 63. YIKON GENOMICS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 64. SCIGENE CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 65. SCIGENE CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 66. SCIGENE CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Preimplantation Genetic Testing Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue